

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ClouDr Group Limited

智雲健康科技集團*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9955)

VOLUNTARY ANNOUNCEMENT

ESTABLISHING A STRATEGIC PARTNERSHIP WITH HONG KONG MAGICURE MEDICAL TO ENHANCE CROSS-BORDER ACCESSIBILITY OF INNOVATIVE MEDICINES AND DEVICES

This announcement is made by ClouDr Group Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) on a voluntary basis to inform its shareholders and potential investors of the recent developments of the Group.

The board (the “**Board**”) of Directors (the “**Directors**”) of the Company is pleased to announce that the Company has recently entered into a non-legally binding strategic cooperation agreement (the “**Agreement**”) with Hong Kong Magicure Medical Co., Ltd. (“**Hong Kong Magicure Medical**”). Pursuant to the Agreement, based on their respective strengths, the two parties will carry out multi-dimensional cooperation on cross-border accessibility of innovative medicines and devices for patients in Mainland China, specifically in the fields of oncology, rare diseases, OTC medicines as well as food for special medical purposes. The two parties will adopt a patient-centric approach to address the needs of critical illness management and chronic disease management, so as to enable Mainland China patients to gain access to high-quality, efficient and internationally-advanced medical and healthcare resources.

The strategic cooperation with Hong Kong Magicure Medical will enable the Company to connect the supply chain and accelerate the pace to tie internationally-advanced medical resources with domestic healthcare needs to provide patients with more convenient cross-border interconnected and sharing services regarding medicines and devices, with a view to effectively reducing the burden of medication on patients and enabling more patients to benefit from the services.

As a pioneer in the field of digital healthcare, the Group has always been committed to exploring healthcare services innovation through new technologies, tools and models to satisfy people's growing demand for medical and healthcare services.

Based on publicly available records and to the best knowledge of the Board having made reasonable inquiries, Hong Kong Magicure Medical and its ultimate beneficial owner(s) are independent from the Company and its connected persons (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")). Further announcement(s) in relation to the possible cooperation with Hong Kong Magicure Medical will be made by the Company as and when appropriate in compliance with the Listing Rules.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
ClouDr Group Limited
*Chairman, Executive Director and
Chief Executive Officer*
Kuang Ming

Hong Kong, 8 September 2023

As at the date of this announcement, the Board comprises Mr. Kuang Ming as the executive Director, Mr. Lee Kar Chung Felix as the non-executive Director, and Dr. Hong Weili, Mr. Zhang Saiyin and Mr. Ang Khai Meng as the independent non-executive Directors.

* *For identification purpose only*